Immuno-Biological Laboratories

4570.TPharmaceutical

Financials · Consolidated

Fiscal year ended	2026-03	2025-03	2024-03	2023-03	2022-03	2021-03
Revenue	¥1.0bn	¥970m	¥817m	¥795m	¥648m	¥603m
Operating income	¥281m	¥209m	¥104m	¥57m^r	−¥122m	−¥241m
Ordinary income	¥301m	¥210m	¥125m	−¥150m	−¥243m	−¥311m
Net income (owners)	¥329m	¥249m	¥187m	−¥290m	−¥259m	−¥319m
Total assets	¥2.2bn	¥1.8bn	¥1.6bn	¥1.4bn	¥1.7bn	¥1.8bn
Net assets / equity	¥1.8bn	¥1.5bn	¥1.3bn	¥1.1bn	¥1.4bn	¥1.6bn
Operating cash flow	¥301m	¥183m	¥134m	¥26m	−¥93m	−¥194m
EPS (basic)	¥35.33	¥26.74	¥20.05	¥-31.1	¥-27.78	¥-34.23

From EDINET filings. Select any figure to open the report it came from. ^r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 13

All Annual 5 Half-year 2 Quarterly 62026 2025 2024 2023 2022

Period	Form	Filed	Figures
2025-04-01 → 2026-03-31	Annual	2026-06-26	197 figures · EDINET
2025-04-01 → 2025-09-30	Half-year	2025-11-14	71 figures · EDINET
2024-04-01 → 2025-03-31	Annual	2025-06-27	194 figures · EDINET
2024-04-01 → 2024-09-30	Half-year	2024-11-14	71 figures · EDINET
2023-04-01 → 2024-03-31	Annual	2024-06-26	192 figures · EDINET
2023-04-01 → 2023-12-31	Quarterly Q3	2024-02-14	49 figures · EDINET
2023-04-01 → 2023-09-30	Quarterly Q2	2023-11-14	73 figures · EDINET
2023-04-01 → 2023-06-30	Quarterly Q1	2023-08-14	47 figures · EDINET
2022-04-01 → 2023-03-31	Annual	2023-06-30	190 figures · EDINET
2022-04-01 → 2022-12-31	Quarterly Q3	2023-02-13	49 figures · EDINET
2022-04-01 → 2022-09-30	Quarterly Q2	2022-11-14	73 figures · EDINET
2022-04-01 → 2022-06-30	Quarterly Q1	2022-08-15	47 figures · EDINET
2021-04-01 → 2022-03-31	Annual	2022-06-30	190 figures · EDINET

25 more reports are still being processed.

Segments · FY ended 2026-03

Segment	External sales	Profit	Assets
Cosmetics	¥3m	−¥609,000	¥37m
Immunity Related	¥1.0bn	¥282m	¥2.1bn
Total	¥1.0bn	¥281m	¥2.2bn

Segment names from EDINET member IDs; not mapped to a common taxonomy.